Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD25 rhMAb for refractory or recurrent adult hemophagocytic lymphohistiocytosis
ChiCTR2400081152Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daclizumab in haemophagocytic lymphohistiocytosis (HLH), sponsored by Union Hospital. Primary endpoints: Overall response rate at end of week 12 and 1-year overall survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
daclizumab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2400081152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081152.